ArticleCureus2025
Neuroendoscopic Diagnosis and Treatment of Adolescent-Onset Aqueductal Stenosis: A Report of Two Cases Demonstrating the Utility of Endoscopic Third Ventriculostomy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendoscopic evaluation and endoscopic third ventriculostomy (ETV) are important in the management of adolescent-onset aqueductal stenosis, a condition often treated with a ventriculoperitoneal shunt (VPS). This condition is relatively rare, and treatment based on an accurate morphological assessment is desirable to provide less invasive and more precise therapy. We report two cases of adolescent-onset aqueductal stenosis (late-onset aqueductal membranous occlusion (LAMO) and late-onset idiopathic aqueductal stenosis (LIAS)) in which a definitive diagnosis was made by direct neuroendoscopic observation, leading to successful ETV and positive clinical outcomes. The clinical courses, imaging findings, intraoperative endoscopic findings, and postoperative courses of the two cases were retrospectively analyzed and compared with a review of the literature. Case 1 was a 16-year-old female patient with LAMO who presented with diplopia. Brain magnetic resonance imaging (MRI) suggested hydrocephalus and a membranous structure within the cerebral aqueduct. The preoperative Endoscopic Third Ventriculostomy Success Score (ETVSS) was 90. After confirming membranous occlusion endoscopically, ETV was performed. Her neurological symptoms completely resolved, and she was discharged with a modified Rankin scale (mRS) score of 0. No recurrence has been observed at 12 months after surgery. Case 2 was a 39-year-old male patient with LIAS who presented with a Glasgow Coma Scale score of 10. He had a history of VPS placement for aqueductal stenosis at age 17. A head computed tomography (CT) revealed acute hydrocephalus due to shunt malfunction. The preoperative ETVSS was 80. The aqueductal stenosis was confirmed endoscopically, diagnosed as LIAS, and ETV was performed. His consciousness improved, and he was transferred to another facility with an mRS score of 1. However, neurological deficits that developed during the acute hydrocephalic episode preceding ETV, such as a constricted visual field and cognitive dysfunction, persisted after surgery. No recurrence has been observed at three months after surgery. No procedure-related complications were observed in either case. In adolescent-onset aqueductal stenosis causing hydrocephalus, a treatment strategy of performing ETV after a definitive neuroendoscopic diagnosis appears safe and effective. This approach may avoid the lifelong risk of shunt-related complications and improve the patient's quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.